Form 4: Catalyst Pharmaceuticals CMO Equity Transaction

Chief Medical Officer William T. Andrews acquired 3,052 shares of Catalyst Pharmaceuticals common stock through the vesting of restricted stock units.

Summary

• William T. Andrews, Chief Medical Officer of Catalyst Pharmaceuticals, Inc., exercised restricted stock units (RSUs) on June 3, 2026.
• A total of 3,052 shares were acquired upon the vesting of RSUs.
• The company withheld 743 shares to satisfy tax obligations associated with the vesting event.
• The reporting person retains 2,309 shares from this specific transaction, bringing total beneficial ownership of derivative securities to 240,195.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral event, as it represents standard executive compensation activity rather than a strategic shift or market-moving event.

Positives

• The transaction reflects the ongoing vesting of equity-based compensation, aligning the interests of the Chief Medical Officer with long-term shareholder value.

Negatives

• The company withheld 743 shares for tax purposes, which is a standard administrative procedure but reduces the net shares received by the executive.

Risks

• No specific operational or financial risks are disclosed in this ownership filing.

Future Outlook

The filing indicates that the remaining derivative securities are scheduled to vest in equal tranches annually through June 2030.

Management Comments

• Each restricted stock unit represents a contingent right to receive one share of the Registrant's common stock upon vesting.

Industry Context

StockSavvy.ai notes that this is a routine disclosure of executive compensation and does not signal a change in corporate strategy or market outlook.

Comparison to Industry Standards

• The use of RSU vesting and net-settlement for tax obligations is standard practice for executive compensation in the biotechnology sector.

Stakeholder Impact

• Minimal impact on shareholders as this is a routine equity compensation event.

Next Steps

• Future tranches of restricted stock units are scheduled to vest annually on June 2nd through 2030.

Key Dates

Keywords

Catalyst Pharmaceuticals, CPRX, Form 4, Insider Trading, Equity Compensation, Chief Medical Officer